Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
DSGN
SellDesign Therapeutics, Inc. · Healthcare · United States · $953M · Avg Vol: $7M/d
COMPANY DESCRIPTION
Design Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing gene-targeted small molecule therapies for serious degenerative diseases. Its proprietary GeneTAC (Gene-Targeting Chimeric) platform enables the precise modulation of disease-causing RNA and protein, offering a novel therapeutic approach. The company distinguishes itself by pioneering this new class of small molecule drugs, aiming to address the root causes of severe genetic conditions with high unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -1.14 | -1.19 | -0.88 | -1.22 | — | -1.18 | -1.36 | -1.59 | — |
| Shares | 55.9M | 56.5M | 56.8M | 60.4M | +8.1% | 62.6M | — | — | — |
| Debt | 3.7M | 3.0M | 2.3M | 1.5M | -25.4% | 2.7M | — | — | — |
| Equity | 327.3M | 277.7M | 242.1M | 212.5M | -13.4% | — | — | — | — |
| Op CF | -51.3M | -58.6M | -43.1M | -54.4M | — | -55.1M | — | — | — |
| Inv CF | -221.0M | 52.5M | 44.0M | 22.9M | — | — | — | — | — |
| Fin CF | 0.2M | 0.7M | 0.5M | 25.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DSGN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DSGN | Design Therapeutics, Inc.(you) | $953M | 34 | Sell |
| IMMX | Immix Biopharma, Inc. | $969M | 34 | Sell |
| LXRX | Lexicon Pharmaceuticals, Inc. | $1.0B | 34 | Sell |
| CADL | Candel Therapeutics, Inc. | $984M | 31 | Sell |
| FTH | Faeth Therapeutics, Inc. | $897M | 32 | Sell |
| NGNE | Neurogene Inc. | $793M | 34 | Sell |
| APMD | Apnimed, Inc. | $1.0B | 36 | Hold |
| SLDB | Solid Biosciences Inc. | $982M | 38 | Hold |
| CLYM | Climb Bio, Inc. | $942M | 39 | Hold |
| AVTX | Avalo Therapeutics, Inc. | $1.0B | 29 | Sell |
Peer medians: ROE -25.6% · P/E 29.5x · Gross margin 58.8%